First-in-Class Antifolate Linker-Drug Platform
Working to overcome antibody drug conjugate (ADC) resistance as therapies move into earlier treatment lines and in combination, our antifolate platform provides a differentiated and validated MOA with a payload designed to overcome systemic side effects. Preclinical results of our frontrunner agent demonstrate both in vitro and in vivo efficacy in various tumor models encompassing multiple tumor-associated antigens (TAAs) targeting ADCs.
Treatment resistance to TOPO1i and TUBi payload ADCs is an apparent problem for cancer patients
Overreliance of ADCs that enter the clinic on two payload MoAs: about 85% use TOPO1i or TUBi payloads
Resistance to TOPO1i and TUBi apparent in the clinic
Need for ADCs with different payload MoA to overcome resistance
Tarantino et al. (2025): “Prior SG treatment [of metastatic breast cancer patients] was associated with inferior outcomes with T-DXd, suggesting cross-resistance between these ADCs.”
Byondis’ Antifolate Payload has Optimal ADC Properties and Overcomes Resistance to TOPO1 Payloads
Byondis Antifolate Platform Advancing to Clinic and Ready for Partnering
Masked Therapeutics (ByonGuard™)
Our innovative universal masking platform, ByonGuard™, is designed to improve the therapeutic index of antibody-based therapies with no bespoke peptides needed.
Phosphonate Linker-Drug Platform (ByonBoosT™)
Our ByonBoost™ phosphonate linker-drug platform is aiming to deliver a range of antibody drug conjugates (ADCs) with high compabilitlity for solid oncology and hematological malignancies.
